Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
GLP-1 agonists are incretin hormones produced by the enteroendocrine L-cells of the small bowel and colon
Individual results will vary from clinical trial averages based on multiple factors Lifestyle modifications remain essential for optimal outcomes with any medication Gradual dose increases help minimise side effects during the adjustment period Tracking hormonal markers helps demonstrate PCOS-specific improvements Patience is important as metabolic changes may precede visible weight loss Key Takeaways Retatrutide is a promising triple-agonist medication targeting GLP-1, GIP, and glucagon receptors that may offer superior benefits for women with PCOS compared to current treatments Clinical trials have shown weight loss of approximately 24%, which could significantly improve PCOS symptoms including insulin resistance, menstrual irregularity, and androgen excess The medication is not yet approved in the UK and remains in phase 3 clinical trials, with potential availability in late 2025 or 2026 Current alternatives including Mounjaro and Wegovy are available now and can provide meaningful benefits for PCOS whilst awaiting newer options Combining medication with lifestyle modifications and regular monitoring of hormonal markers offers the best approach for comprehensive PCOS management When to Seek Professional Advice If you suspect you have PCOS or have received a diagnosis and feel your current treatment is inadequate, speaking with a healthcare professional is the appropriate first step
And right around that moment, almost everybody ends up typing the same thing into Google: probiotics and Ozempic together. It makes sense
For the broader context of peptide-based fat loss options beyond the GLP-1 class, the peptides for fat loss guide and best peptides for weight loss guide provide a comparative framework
When you receive your vial, move it to a freezer immediately if you are not planning to reconstitute it within 24 hours
On the right, GIP binding to a G protein-bound GIP receptor is shown (PDB 7RA3)
